This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Malwarebytes files US counterclaims against Enigma in false advertising case

( August 5, 2024, 22:31 GMT | Official Statement) -- MLex Summary: Malwarebytes filed US counterclaims against Enigma Software Group in its case over alleged false advertising and deceptive practices. “For the last eight years, Enigma has tried to use this litigation to force Malwarebytes to rewrite its software to benefit Enigma and to describe Enigma’s products only in terms that Enigma approves. Instead of changing the deceptive business practices that led Malwarebytes to classify Enigma’s products as potentially unwanted programs, Enigma has tried to bully Malwarebytes into recanting the latter’s protected speech. All the while, Enigma has engaged in the very misconduct it wrongly alleges Malwarebytes committed,” it claims. See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents